Clinical significance of anemia in chronic heart failure in patients infected with human immunodeficiency virus

Abstract

Anemia, as the most common hematological complication of HIV infection, is one of the key indicators of its severity and a predictor of death from its complications. Within 3 years, 240 patients with HIV infection were examined in a multidisciplinary hospital. In the examined group, 160 (66.60 %) people had clinical, instrumental and laboratory signs of CHF. Among them, 94 patients (58.75 %) had anemia of varying severity. The presence of CHF 2.75 times increases the chances of developing anemia in HIV-infected people. The development of anemia is associated with the development of CKD stage 3A and above, an increase in the volume of the left atrium, the development of diastolic dysfunction of the left ventricle and severe CHF with a concentration of NT-proBNP ≥ 1500 pg/ml in blood plasma. In patients with CHF and HIV infection, determining the concentration of NT-proBNP ≥ 170 pg/ml is associated with the development of anemia, which gives this test additional clinical significance. Reduced transferrin less than 200 mg/dl 10.99 times increases the chances of developing severe CHF with NT-proBNP ≥ 1500 pg/ml, which makes it recommended to determine the level of serum transferrin in all patients with HIV infection and CHF in order to predict the development of severe CHF with NT-proBNP ≥ 1500 pg/ml.